Communications Biology (Sep 2023)

In vivo label-free optical signatures of chemotherapy response in human pancreatic ductal adenocarcinoma patient-derived xenografts

  • Jaena Park,
  • Janet E. Sorrells,
  • Eric J. Chaney,
  • Amro M. Abdelrahman,
  • Jennifer A. Yonkus,
  • Jennifer L. Leiting,
  • Heidi Nelson,
  • Jonathan J. Harrington,
  • Edita Aksamitiene,
  • Marina Marjanovic,
  • Peter D. Groves,
  • Colleen Bushell,
  • Mark J. Truty,
  • Stephen A. Boppart

DOI
https://doi.org/10.1038/s42003-023-05368-y
Journal volume & issue
Vol. 6, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Pancreatic cancer is a devastating disease often detected at later stages, necessitating swift and effective chemotherapy treatment. However, chemoresistance is common and its mechanisms are poorly understood. Here, label-free multi-modal nonlinear optical microscopy was applied to study microstructural and functional features of pancreatic tumors in vivo to monitor inter- and intra-tumor heterogeneity and treatment response. Patient-derived xenografts with human pancreatic ductal adenocarcinoma were implanted into mice and characterized over five weeks of intraperitoneal chemotherapy (FIRINOX or Gem/NabP) with known responsiveness/resistance. Resistant and responsive tumors exhibited a similar initial metabolic response, but by week 5 the resistant tumor deviated significantly from the responsive tumor, indicating that a representative response may take up to five weeks to appear. This biphasic metabolic response in a chemoresistant tumor reveals the possibility of intra-tumor spatiotemporal heterogeneity of drug responsiveness. These results, though limited by small sample size, suggest the possibility for further work characterizing chemoresistance mechanisms using nonlinear optical microscopy.